Merck KGaA suffers major blow as MS drug fails in late-stage trials

Germany's Merck KGaA
said its experimental multiple sclerosis drug
evobrutinib did not meet the primary goal in highly anticipated
late-stage trials, dealing a major blow to the company's...

Related Keywords

Germany ,German ,Belen Garijo ,Josie Kao ,Merck Kga ,Sanofi Aubagio ,Drug Administration ,Novartis ,Reuters ,Ludwig Burger Editing ,Bill Berkrot ,Markets ,